5-ARIs Do Not Increase Prostate Cancer Mortality
Data on whether 5-ARIs increase the risk of prostate cancer-specific mortality have been mixed.
Data on whether 5-ARIs increase the risk of prostate cancer-specific mortality have been mixed.
A study of 3090 patients with HIV seen at a tertiary care hospital from June 2019 to June 2020 revealed a 1.8% prevalence of advanced chronic kidney disease, an approximately 4-fold increase from 2008-2010.
For those aged 40 to 59 years, the decision to initiate low-dose aspirin for primary prevention of CVD should be individualized
An analysis of data discovered a link between treatment with androgen deprivation therapy and new diagnoses of incident depression and anxiety in men with prostate cancer.
Among men with ischemic heart disease, coprescription of nitrates and PDE5 inhibitors not linked to increased risk for cardiovascular events
Adverse effects of induction therapies for lupus nephritis may limit their use.
Patients with poor performance status have been excluded from pivotal trials on metastatic renal cell carcinoma.
Investigators describe the type and frequency of adverse reactions and how clinicians managed them.
More than three-quarters of COVID-19-associated drug-drug interactions could have been identified
In a study of patients with CKD and/or heart failure on RAASi therapy, the proportion of patients who received dose reductions or had therapy discontinued after new-onset hyperkalemia increased with hyperkalemia severity.